SOLID TUMOURS:@0.084848:0.038601:0.266058:0.038601:0.266058:0.019343:0.084848:0.019343:0.011712:0.020438:0.010866:0.005315:0.017498:0.006515:0.010019:0.015405:0.021613:0.020438:0.015405:0.014276:0.011712
66:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
In the pre-chemo setting (Prevail trial) , :@0.102424:0.096166:0.480484:0.096166:0.480484:0.080410:0.102424:0.080410:0.004349:0.011738:0.007851:0.006523:0.011738:0.012508:0.007851:0.013123:0.005713:0.012508:0.006388:0.012450:0.011738:0.012508:0.018049:0.012604:0.007841:0.007466:0.012508:0.006523:0.006523:0.003848:0.011738:0.012950:0.007841:0.007100:0.011392:0.005711:0.012508:0.010660:0.013143:0.003848:0.003848:0.007851:0.006523:0.005792:0.003848:0.013143:0.003848:0.007100:0.006206:0.005330:0.005330
9:@0.463606:0.090547:0.469821:0.090547:0.469821:0.081361:0.463606:0.081361:0.006215
enzalutamide also showed a 29% reduc-:@0.084244:0.112490:0.475171:0.112490:0.475171:0.096734:0.084244:0.096734:0.012508:0.011738:0.008178:0.013143:0.003848:0.011699:0.006523:0.013143:0.018049:0.003848:0.013181:0.012508:0.008140:0.013143:0.003848:0.007466:0.012604:0.008140:0.007466:0.011738:0.012604:0.015990:0.012508:0.013181:0.008140:0.013143:0.008140:0.010660:0.010660:0.014913:0.008140:0.005713:0.012508:0.013181:0.011699:0.012450:0.006388
tion in the death rate at the time of data :@0.084244:0.128815:0.480501:0.128815:0.480501:0.113059:0.084244:0.113059:0.006523:0.003848:0.012604:0.011738:0.006529:0.003848:0.011738:0.006542:0.006523:0.011738:0.012508:0.006529:0.013181:0.012508:0.013143:0.006523:0.011738:0.006531:0.005792:0.013143:0.006523:0.012508:0.006529:0.013143:0.006523:0.006542:0.006523:0.011738:0.012508:0.006527:0.006523:0.003848:0.018049:0.012508:0.006542:0.012604:0.006042:0.006531:0.013181:0.013143:0.006523:0.013143:0.005330
cut-off and benefit on the secondary end-:@0.084244:0.145140:0.475154:0.145140:0.475154:0.129384:0.084244:0.129384:0.012450:0.011699:0.006523:0.006388:0.012604:0.006090:0.006042:0.004530:0.013143:0.011738:0.013181:0.004532:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.004524:0.012604:0.011738:0.004526:0.006523:0.011738:0.012508:0.004524:0.007466:0.012508:0.012450:0.012604:0.011738:0.013181:0.013143:0.005792:0.010314:0.004526:0.012508:0.011738:0.013181:0.006388
points.  The  same  side  effect  profile  was :@0.084244:0.161465:0.480476:0.161465:0.480476:0.145709:0.084244:0.145709:0.013123:0.012604:0.003848:0.011738:0.006523:0.007466:0.005330:0.005330:0.004630:0.008197:0.011738:0.012508:0.005330:0.004624:0.007466:0.013143:0.018049:0.012508:0.005330:0.004630:0.007466:0.003848:0.013181:0.012508:0.005330:0.004639:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.005330:0.004634:0.013123:0.005715:0.012604:0.004686:0.004686:0.003848:0.012508:0.005330:0.004626:0.015990:0.013143:0.007466:0.005330
observed.:@0.084244:0.177790:0.177416:0.177790:0.177416:0.162034:0.084244:0.162034:0.012604:0.013123:0.007466:0.012508:0.005792:0.010660:0.012508:0.013181:0.005330
Chemotherapy:@0.084242:0.210774:0.241603:0.210774:0.241603:0.192753:0.084242:0.192753:0.016677:0.012828:0.013683:0.020098:0.013683:0.006414:0.012828:0.013683:0.006842:0.014111:0.014111:0.012401
In patients with metastatic disease show-:@0.084242:0.228247:0.475125:0.228247:0.475125:0.212491:0.084242:0.212491:0.004349:0.011738:0.007466:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007466:0.015990:0.003848:0.006523:0.011738:0.007466:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.007466:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.007478:0.007466:0.011738:0.012604:0.015990:0.006388
ing progression after  hormonal manage-:@0.084242:0.244571:0.475177:0.244571:0.475177:0.228815:0.084242:0.228815:0.003848:0.011738:0.012950:0.008678:0.013123:0.005715:0.012604:0.012950:0.005709:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.008678:0.013143:0.006042:0.006523:0.012508:0.005792:0.005330:0.003335:0.011738:0.012604:0.006317:0.018049:0.012604:0.011738:0.013143:0.003848:0.008678:0.018049:0.013143:0.011738:0.013143:0.012950:0.012508:0.006388
ment, chemotherapy is indicated.:@0.084242:0.260896:0.401935:0.260896:0.401935:0.245140:0.084242:0.245140:0.018049:0.012508:0.011738:0.006523:0.005330:0.005330:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.003848:0.007466:0.005330:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.005330
Docetaxel:@0.102426:0.277221:0.199023:0.277221:0.199023:0.261187:0.102426:0.261187:0.013470:0.012315:0.012315:0.012315:0.005773:0.012700:0.010776:0.012315:0.004618
  has  been  shown  to  reduce :@0.199023:0.277221:0.480474:0.277221:0.480474:0.261465:0.199023:0.261465:0.005330:0.004108:0.011738:0.013143:0.007466:0.005330:0.004108:0.013123:0.012508:0.012508:0.011738:0.005330:0.004104:0.007466:0.011738:0.012604:0.015990:0.011738:0.005330:0.004104:0.006523:0.012604:0.005330:0.004101:0.005713:0.012508:0.013181:0.011699:0.012450:0.012508:0.005330
pain, lower  PSA  levels and increase the :@0.084242:0.293546:0.480495:0.293546:0.480495:0.277790:0.084242:0.277790:0.013123:0.013143:0.003848:0.011738:0.005330:0.009794:0.003848:0.012604:0.015990:0.012508:0.005792:0.005330:0.004453:0.011392:0.009583:0.014239:0.005330:0.004455:0.003848:0.012508:0.010660:0.012508:0.003848:0.007466:0.009794:0.013143:0.011738:0.013181:0.009794:0.003848:0.011738:0.012450:0.005711:0.012508:0.013143:0.007466:0.012508:0.009794:0.006523:0.011738:0.012508:0.005330
survival  rate.  Docetaxel can be used at :@0.084242:0.309871:0.480486:0.309871:0.480486:0.294115:0.084242:0.294115:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.003997:0.005792:0.013143:0.006523:0.012508:0.005330:0.005330:0.003974:0.014316:0.012604:0.012450:0.012508:0.006523:0.013143:0.009236:0.012508:0.003848:0.009313:0.012450:0.013143:0.011738:0.009313:0.013123:0.012508:0.009313:0.011699:0.007466:0.012508:0.013181:0.009313:0.013143:0.006523:0.005330
three-weekly intervals or at a lower dose :@0.084242:0.326195:0.480467:0.326195:0.480467:0.310439:0.084242:0.310439:0.006523:0.011738:0.005707:0.012508:0.012508:0.006388:0.015990:0.012508:0.012508:0.009660:0.003848:0.010314:0.007909:0.003848:0.011738:0.006523:0.012508:0.005792:0.010660:0.013143:0.003848:0.007466:0.007920:0.012604:0.005792:0.007909:0.013143:0.006523:0.007909:0.013143:0.007909:0.003848:0.012604:0.015990:0.012508:0.005792:0.007909:0.013181:0.012604:0.007466:0.012508:0.005330
at weekly intervals. The addition of pred-:@0.084242:0.342520:0.475163:0.342520:0.475163:0.326764:0.084242:0.326764:0.013143:0.006523:0.007582:0.015990:0.012508:0.012508:0.009660:0.003848:0.010314:0.007582:0.003848:0.011738:0.006523:0.012508:0.005792:0.010660:0.013143:0.003848:0.007466:0.005330:0.007593:0.008197:0.011738:0.012508:0.007582:0.013143:0.013181:0.013181:0.003848:0.006523:0.003848:0.012604:0.011738:0.007582:0.012604:0.006042:0.007582:0.013123:0.005715:0.012508:0.013181:0.006388
nisone 10 mg daily will improve response.:@0.084242:0.358845:0.465288:0.358845:0.465288:0.343089:0.084242:0.343089:0.011738:0.003848:0.007466:0.012604:0.011738:0.012508:0.005330:0.010660:0.010660:0.005330:0.018049:0.012950:0.005330:0.013181:0.013143:0.003848:0.003848:0.010314:0.005330:0.015990:0.003848:0.003848:0.003848:0.005330:0.003848:0.018049:0.013123:0.005730:0.012604:0.010660:0.012508:0.005330:0.005707:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.005330
Cabazitaxel,:@0.102426:0.375170:0.220575:0.375170:0.220575:0.359136:0.102426:0.359136:0.015009:0.012700:0.012700:0.012700:0.008852:0.004618:0.005773:0.012700:0.010776:0.012315:0.004618:0.005388
 a second-generation  tax-:@0.220575:0.375170:0.475165:0.375170:0.475165:0.359414:0.220575:0.359414:0.008832:0.013143:0.008832:0.007466:0.012508:0.012450:0.012604:0.011738:0.013181:0.006388:0.012950:0.012508:0.011738:0.012508:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.003477:0.006523:0.013143:0.009236:0.006388
ane, has been shown to increase survival :@0.084242:0.391495:0.480484:0.391495:0.480484:0.375739:0.084242:0.375739:0.013143:0.011738:0.012508:0.005330:0.006796:0.011738:0.013143:0.007466:0.006812:0.013123:0.012508:0.012508:0.011738:0.006802:0.007466:0.011738:0.012604:0.015990:0.011738:0.006798:0.006523:0.012604:0.006796:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.006812:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330
in patients who have failed docetaxel :@0.084242:0.407819:0.480482:0.407819:0.480482:0.392063:0.084242:0.392063:0.003848:0.011738:0.012700:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.012700:0.015990:0.011738:0.012604:0.012700:0.011738:0.013143:0.010660:0.012508:0.012700:0.006042:0.013143:0.003848:0.003848:0.012508:0.013181:0.012700:0.013181:0.012604:0.012450:0.012508:0.006523:0.013143:0.009236:0.012508:0.003848:0.005330
therapy.  In  a  phase  III trial,   cabazitaxel :@0.084242:0.424144:0.480475:0.424163:0.480475:0.408407:0.084242:0.408388:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330:0.003348:0.004349:0.011738:0.005330:0.003354:0.013143:0.005330:0.003358:0.013123:0.011738:0.013143:0.007466:0.012508:0.005330:0.003356:0.004349:0.004349:0.004349:0.008698:0.006523:0.005792:0.003848:0.013143:0.003848:0.005330:0.012431:0.005330:0.003356:0.012450:0.013143:0.013123:0.013143:0.008178:0.003848:0.006523:0.013143:0.009236:0.012508:0.003848:0.385353
10:@0.344881:0.418544:0.357311:0.418544:0.357311:0.409359:0.344881:0.409359:0.006215:0.006215
plus  prednisone  significantly  increased :@0.084246:0.440488:0.480476:0.440488:0.480476:0.424732:0.084246:0.424732:0.013123:0.003848:0.011699:0.007466:0.005330:0.011526:0.013123:0.005715:0.012508:0.013181:0.011738:0.003848:0.007466:0.012604:0.011738:0.012508:0.005330:0.011507:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.003848:0.010314:0.005330:0.011517:0.003848:0.011738:0.012450:0.005715:0.012508:0.013143:0.007466:0.012508:0.013181:0.005330
survival compared with mitoxantrone plus :@0.084246:0.456813:0.480486:0.456813:0.480486:0.441057:0.084246:0.441057:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.006152:0.012450:0.012604:0.018049:0.013123:0.013143:0.005713:0.012508:0.013181:0.006138:0.015990:0.003848:0.006523:0.011738:0.006138:0.018049:0.003848:0.006523:0.012604:0.009236:0.013143:0.011738:0.006523:0.005709:0.012604:0.011738:0.012508:0.006133:0.013123:0.003848:0.011699:0.007466:0.005330
prednisone in men whose disease had :@0.084246:0.473138:0.480505:0.473138:0.480505:0.457382:0.084246:0.457382:0.013123:0.005715:0.012508:0.013181:0.011738:0.003848:0.007466:0.012604:0.011738:0.012508:0.012027:0.003848:0.011738:0.012027:0.018049:0.012508:0.011738:0.012027:0.015990:0.011738:0.012604:0.007466:0.012508:0.012027:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.012027:0.011738:0.013143:0.013181:0.005330
progressed on docetaxel. An initial report :@0.084246:0.489463:0.480501:0.489463:0.480501:0.473707:0.084246:0.473707:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.012508:0.013181:0.006600:0.012604:0.011738:0.006600:0.013181:0.012604:0.012450:0.012508:0.006523:0.013143:0.009236:0.012508:0.003848:0.005330:0.006591:0.014239:0.011738:0.006600:0.003848:0.011738:0.003848:0.006523:0.003848:0.013143:0.003848:0.006600:0.005711:0.012508:0.013123:0.012604:0.005792:0.006523:0.005330
of a phase III trial found that a dose of :@0.084246:0.505787:0.480448:0.505787:0.480448:0.490031:0.084246:0.490031:0.012604:0.006042:0.009352:0.013143:0.009352:0.013123:0.011738:0.013143:0.007466:0.012508:0.009352:0.004349:0.004349:0.004349:0.009352:0.006523:0.005792:0.003848:0.013143:0.003848:0.009352:0.006042:0.012604:0.011699:0.011738:0.013181:0.009352:0.006523:0.011738:0.013143:0.006523:0.009352:0.013143:0.009352:0.013181:0.012604:0.007466:0.012508:0.009352:0.012604:0.006042:0.005330
20 mg/m  was as effective and less toxic :@0.084246:0.522112:0.480503:0.522122:0.480503:0.506366:0.084246:0.506356:0.010660:0.010660:0.007370:0.018049:0.012950:0.008409:0.018049:0.006209:0.007370:0.015990:0.013143:0.007466:0.007370:0.013143:0.007466:0.007370:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.007370:0.013143:0.011738:0.013181:0.007358:0.003848:0.012508:0.007466:0.007466:0.007370:0.006523:0.012604:0.009236:0.003848:0.012450:0.242840
2:@0.170387:0.516503:0.176601:0.516503:0.176601:0.507317:0.170387:0.507317:0.006215
than the approved dose of 25 mg/m . This :@0.084240:0.538447:0.480481:0.538448:0.480481:0.522692:0.084240:0.522691:0.006523:0.011738:0.013143:0.011738:0.005276:0.006523:0.011738:0.012508:0.005276:0.013143:0.013123:0.013123:0.005719:0.012604:0.010660:0.012508:0.013181:0.005280:0.013181:0.012604:0.007466:0.012508:0.005282:0.012604:0.006042:0.005276:0.010660:0.010660:0.005292:0.018049:0.012950:0.008409:0.018049:0.006215:0.005330:0.005280:0.008197:0.011738:0.003848:0.007466:0.219114
2:@0.427074:0.532829:0.433289:0.532829:0.433289:0.523643:0.427074:0.523643:0.006215
mitigates the side effects typical of taxa-:@0.084234:0.554773:0.475132:0.554773:0.475132:0.539017:0.084234:0.539017:0.018049:0.003848:0.006523:0.003848:0.012950:0.013143:0.006523:0.012508:0.007466:0.007389:0.006523:0.011738:0.012508:0.007389:0.007466:0.003848:0.013181:0.012508:0.007389:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.007389:0.006523:0.010314:0.013123:0.003848:0.012450:0.013143:0.003848:0.007401:0.012604:0.006042:0.007389:0.006523:0.013143:0.009236:0.013143:0.006388
nes to a level similar to and less than those :@0.084234:0.571098:0.480493:0.571098:0.480493:0.555342:0.084234:0.555342:0.011738:0.012508:0.007466:0.005011:0.006523:0.012604:0.005003:0.013143:0.005022:0.003848:0.012508:0.010660:0.012508:0.003848:0.005022:0.007466:0.003848:0.018049:0.003848:0.003848:0.013143:0.005792:0.005022:0.006523:0.012604:0.005003:0.013143:0.011738:0.013181:0.005013:0.003848:0.012508:0.007466:0.007466:0.005022:0.006523:0.011738:0.013143:0.011738:0.005005:0.006523:0.011738:0.012604:0.007466:0.012508:0.005330
of docetaxel.:@0.084234:0.587422:0.209541:0.587422:0.209541:0.571667:0.084234:0.571667:0.012604:0.006042:0.005330:0.013181:0.012604:0.012450:0.012508:0.006523:0.013143:0.009236:0.012508:0.003848:0.005330
Intravenous radiation: Radium-223 :@0.084242:0.620403:0.444717:0.620403:0.444717:0.602382:0.084242:0.602382:0.005987:0.012828:0.006414:0.006842:0.014111:0.011973:0.013683:0.012828:0.013683:0.012828:0.009407:0.005987:0.006842:0.014111:0.014111:0.005131:0.014111:0.006414:0.005131:0.013683:0.012828:0.005987:0.005987:0.012401:0.014111:0.014111:0.005131:0.012828:0.020098:0.008980:0.011973:0.011973:0.011973:0.005987
(Xofigo):@0.084242:0.638204:0.167626:0.638204:0.167626:0.620183:0.084242:0.620183:0.008125:0.014539:0.013683:0.005559:0.005559:0.014111:0.013683:0.008125
Radium-223 :@0.084242:0.655673:0.200851:0.655673:0.200851:0.639639:0.084242:0.639639:0.011161:0.012700:0.012700:0.004618:0.011545:0.018088:0.008082:0.010776:0.010776:0.010776:0.005388
(223-Ra), a new intravenously :@0.200928:0.655673:0.480463:0.655673:0.480463:0.639917:0.200928:0.639917:0.007100:0.010660:0.010660:0.010660:0.006388:0.011680:0.013143:0.007100:0.005330:0.005407:0.013143:0.005407:0.011738:0.012508:0.015990:0.005407:0.003848:0.011738:0.006523:0.005792:0.013143:0.010660:0.012508:0.011738:0.012604:0.011699:0.007466:0.003848:0.010314:0.005330
administrated radionuclide (alpha parti-:@0.084242:0.671998:0.475133:0.671998:0.475133:0.656242:0.084242:0.656242:0.013143:0.013181:0.018049:0.003848:0.011738:0.003848:0.007466:0.006523:0.005792:0.013143:0.006523:0.012508:0.013181:0.011064:0.005792:0.013143:0.013181:0.003848:0.012604:0.011738:0.011699:0.012450:0.003848:0.003848:0.013181:0.012508:0.011064:0.007100:0.013143:0.003848:0.013123:0.011738:0.013143:0.011064:0.013123:0.013143:0.005792:0.006523:0.003848:0.006388
cles), demonstrated  improvement  in  sur-:@0.084242:0.688322:0.475167:0.688322:0.475167:0.672566:0.084242:0.672566:0.012450:0.003848:0.012508:0.007466:0.007100:0.005330:0.009198:0.013181:0.012508:0.018049:0.012604:0.011738:0.007466:0.006523:0.005792:0.013143:0.006523:0.012508:0.013181:0.005330:0.003852:0.003848:0.018049:0.013123:0.005717:0.012604:0.010660:0.012508:0.018049:0.012508:0.011738:0.006523:0.005330:0.003850:0.003848:0.011738:0.005330:0.003856:0.007466:0.011699:0.005792:0.006388
vival  in patients with castration-resistant :@0.084242:0.704647:0.480488:0.704647:0.480488:0.688891:0.084242:0.688891:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.006094:0.003848:0.011738:0.011411:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.011411:0.015990:0.003848:0.006523:0.011738:0.011411:0.012450:0.013143:0.007466:0.006523:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.006388:0.005707:0.012508:0.007466:0.003848:0.007466:0.006523:0.013143:0.011738:0.006523:0.005330
prostate cancer with bone-only metastat-:@0.084242:0.720972:0.475160:0.720972:0.475160:0.705216:0.084242:0.705216:0.013123:0.005715:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.005503:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005503:0.015990:0.003848:0.006523:0.011738:0.005503:0.013123:0.012604:0.011738:0.012508:0.006388:0.012604:0.011726:0.003848:0.010314:0.005503:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.006388
ic disease. It can also be used to improve :@0.084242:0.737297:0.480440:0.737297:0.480440:0.721541:0.084242:0.721541:0.003848:0.012450:0.005965:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.005965:0.004349:0.006523:0.005965:0.012450:0.013143:0.011738:0.005965:0.013143:0.003848:0.007466:0.012604:0.005977:0.013123:0.012508:0.005965:0.011699:0.007466:0.012508:0.013181:0.005965:0.006523:0.012604:0.005965:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.005330
pain symptoms.:@0.084242:0.753621:0.230350:0.753621:0.230350:0.737866:0.084242:0.737866:0.013123:0.013143:0.003848:0.011738:0.005330:0.007466:0.010314:0.018049:0.013123:0.006523:0.012604:0.018049:0.007466:0.005330
In the phase III Alsympca trial , a month-:@0.102426:0.769946:0.475144:0.769957:0.475144:0.754202:0.102426:0.754190:0.004349:0.011738:0.004445:0.006523:0.011738:0.012508:0.004445:0.013123:0.011738:0.013143:0.007466:0.012508:0.004445:0.004349:0.004349:0.004349:0.004445:0.014239:0.003848:0.007466:0.010314:0.018049:0.013123:0.012450:0.013143:0.004458:0.006523:0.005792:0.003848:0.013143:0.003848:0.012429:0.005330:0.004445:0.013143:0.004445:0.018049:0.012604:0.011738:0.006523:0.011719:-0.111231
11:@0.368326:0.764338:0.380756:0.764338:0.380756:0.755153:0.368326:0.755153:0.006215:0.006215
ly infusion  was well tolerated, and im-:@0.084235:0.786282:0.475123:0.786282:0.475123:0.770526:0.084235:0.770526:0.003848:0.010314:0.012777:0.003848:0.011738:0.006042:0.011699:0.007466:0.003848:0.012604:0.011738:0.005330:0.007437:0.015990:0.013143:0.007466:0.012777:0.015990:0.012508:0.003848:0.003848:0.012777:0.006523:0.012604:0.003848:0.012508:0.005792:0.013143:0.006523:0.012496:0.013181:0.005330:0.012777:0.013143:0.011738:0.013181:0.012777:0.003848:0.018049:0.006388
proved overall survival (14:@0.084235:0.802607:0.328109:0.802607:0.328109:0.786851:0.084235:0.786851:0.013123:0.005715:0.012604:0.010660:0.012508:0.013181:0.006042:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.006042:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.006058:0.007100:0.010660:0.010660
 vs :@0.328132:0.802607:0.357631:0.802607:0.357631:0.786851:0.328132:0.786851:0.006042:0.010660:0.007466:0.005330
11.2 months, :@0.358343:0.802607:0.480475:0.802607:0.480475:0.786851:0.358343:0.786851:0.010660:0.010660:0.005330:0.010660:0.006042:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.005330:0.005330
HR 0.7, 95% CI 0.55-0.88), and assessment :@0.084235:0.818932:0.480471:0.818932:0.480471:0.803176:0.084235:0.803176:0.013143:0.011680:0.007004:0.010660:0.005330:0.010660:0.005330:0.007004:0.010660:0.010660:0.014913:0.007004:0.015644:0.004349:0.007004:0.010660:0.005330:0.010660:0.010660:0.006388:0.010660:0.005330:0.010660:0.010660:0.007100:0.005330:0.007020:0.013143:0.011738:0.013181:0.007004:0.013143:0.007466:0.007466:0.012508:0.007466:0.007466:0.018049:0.012508:0.011738:0.006523:0.005330
of  all  secondary  endpoints  (time  to  first :@0.084235:0.835257:0.480482:0.835257:0.480482:0.819501:0.084235:0.819501:0.012604:0.006042:0.005330:0.005199:0.013143:0.003848:0.003848:0.005330:0.005215:0.007466:0.012508:0.012450:0.012604:0.011738:0.013181:0.013143:0.005792:0.010314:0.005330:0.005203:0.012508:0.011738:0.013181:0.013123:0.012604:0.003848:0.011738:0.006523:0.007466:0.005330:0.005201:0.007100:0.006523:0.003848:0.018049:0.012508:0.005330:0.005203:0.006523:0.012604:0.005330:0.005197:0.004686:0.004686:0.005792:0.007466:0.006523:0.005330
symptomatic skeletal event and biochem-:@0.523635:0.096156:0.914554:0.096156:0.914554:0.080400:0.523635:0.080400:0.007466:0.010314:0.018049:0.013123:0.006523:0.012604:0.018049:0.013143:0.006523:0.003848:0.012450:0.004156:0.007466:0.009660:0.012508:0.003848:0.012508:0.006523:0.013143:0.003848:0.004156:0.012508:0.010660:0.012508:0.011738:0.006523:0.004147:0.013143:0.011738:0.013181:0.004156:0.013123:0.003848:0.012604:0.012450:0.011738:0.012508:0.018049:0.006388
ical parameters) was positive as well.:@0.523635:0.112666:0.868036:0.112666:0.868036:0.096910:0.523635:0.096910:0.003848:0.012450:0.013143:0.003848:0.005330:0.013123:0.013143:0.005792:0.013143:0.018049:0.012508:0.006523:0.012508:0.005792:0.007466:0.007100:0.005330:0.015990:0.013143:0.007466:0.005330:0.013123:0.012604:0.007466:0.003848:0.006523:0.003848:0.010660:0.012508:0.005330:0.013143:0.007466:0.005330:0.015990:0.012508:0.003848:0.003848:0.005330
Side effects included myelosuppression :@0.541819:0.129176:0.919883:0.129176:0.919883:0.113420:0.541819:0.113420:0.009583:0.003848:0.013181:0.012508:0.007832:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.007820:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.013181:0.007832:0.018049:0.010314:0.012508:0.003848:0.012604:0.007466:0.011699:0.013123:0.013123:0.005719:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330
and mild diarrhoea,  however  patients :@0.523635:0.145686:0.919873:0.145686:0.919873:0.129930:0.523635:0.129930:0.013143:0.011738:0.013181:0.014913:0.018049:0.003848:0.003848:0.013181:0.014913:0.013181:0.003848:0.013143:0.005792:0.006337:0.011738:0.012604:0.012508:0.013143:0.005330:0.005330:0.009567:0.011738:0.012604:0.015990:0.012508:0.010660:0.012508:0.005792:0.005330:0.009571:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
generally tolerate these very well. Re-:@0.523635:0.162196:0.914545:0.162196:0.914545:0.146440:0.523635:0.146440:0.012950:0.012508:0.011738:0.012508:0.005792:0.013143:0.003848:0.003848:0.010314:0.013739:0.006523:0.012604:0.003848:0.012508:0.005792:0.013143:0.006523:0.012508:0.013739:0.006523:0.011738:0.012508:0.007466:0.012508:0.013739:0.010660:0.012508:0.005792:0.010314:0.013739:0.015990:0.012508:0.003848:0.003848:0.005330:0.013739:0.011680:0.012508:0.006388
grettably, the treatment is costly and few :@0.523635:0.178706:0.919877:0.178706:0.919877:0.162950:0.523635:0.162950:0.012950:0.005709:0.012508:0.006523:0.006523:0.013143:0.013123:0.003848:0.010314:0.005330:0.006639:0.006523:0.011738:0.012508:0.006639:0.006523:0.005713:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.006629:0.003848:0.007466:0.006639:0.012450:0.012604:0.007466:0.006523:0.003848:0.010314:0.006639:0.013143:0.011738:0.013181:0.006639:0.006042:0.012508:0.015990:0.005330
funders will allow access to 223-Ra.:@0.523635:0.195216:0.848813:0.195216:0.848813:0.179460:0.523635:0.179460:0.006042:0.011699:0.011738:0.013181:0.012508:0.005792:0.007466:0.005330:0.015990:0.003848:0.003848:0.003848:0.005330:0.013143:0.003848:0.003848:0.012604:0.015990:0.005330:0.013143:0.012450:0.012450:0.012508:0.007466:0.007466:0.005330:0.006523:0.012604:0.005330:0.010660:0.010660:0.010660:0.006388:0.011680:0.013143:0.005330
REFERENCES:@0.523635:0.225299:0.634471:0.225299:0.634471:0.209266:0.523635:0.209266:0.011161:0.010006:0.009236:0.010006:0.011161:0.010006:0.014239:0.015009:0.010006:0.010006
1. :@0.523636:0.242379:0.542588:0.242379:0.542588:0.228374:0.523636:0.228374:0.009476:0.004738:0.004738
 Kirby RS, Patel MI. :@0.559983:0.242379:0.709391:0.242379:0.709391:0.228374:0.559983:0.228374:0.000000:0.010109:0.003421:0.005148:0.011665:0.009168:0.005018:0.010382:0.008518:0.004738:0.005015:0.010126:0.011682:0.005798:0.011118:0.003421:0.005020:0.015719:0.003866:0.004738:0.004738
Fast Facts: Prostate Can-:@0.709663:0.242379:0.914544:0.242379:0.914544:0.228374:0.709663:0.228374:0.008296:0.011682:0.006636:0.005798:0.005018:0.008296:0.011682:0.011067:0.005798:0.006636:0.004738:0.005015:0.010126:0.005148:0.011203:0.006636:0.005798:0.011682:0.005798:0.011118:0.005006:0.013906:0.011682:0.010434:0.005679
cer.:@0.559983:0.256831:0.592053:0.256831:0.592053:0.242826:0.559983:0.242826:0.011067:0.011118:0.005148:0.004738
 6th ed. Oxford: Health Press; 2009;6-7.:@0.592053:0.256831:0.905361:0.256831:0.905361:0.242826:0.592053:0.242826:0.004738:0.009476:0.005798:0.010434:0.004738:0.011118:0.011716:0.004738:0.004738:0.014864:0.008210:0.005371:0.011203:0.005030:0.011716:0.004738:0.004738:0.011682:0.011118:0.011682:0.003421:0.005798:0.010434:0.004738:0.010126:0.005068:0.011118:0.006636:0.006636:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.005679:0.009476:0.004738
2. :@0.523636:0.271284:0.542588:0.271284:0.542588:0.257278:0.523636:0.257278:0.009476:0.004738:0.004738
  Ries  L,:@0.559983:0.271284:0.615192:0.271284:0.615192:0.257278:0.559983:0.257278:0.004738:-0.004738:0.010382:0.003421:0.011118:0.006636:0.004738:0.006274:0.007902:0.004738
 et  al. SEER Cancer  Statistics Re-:@0.615192:0.271284:0.914561:0.271284:0.914561:0.257278:0.615192:0.257278:0.011015:0.011118:0.005798:0.004738:0.006265:0.011682:0.003421:0.004738:0.011015:0.008518:0.009168:0.009168:0.010382:0.011015:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.006264:0.008518:0.005798:0.011682:0.005798:0.003421:0.006636:0.005798:0.003421:0.011067:0.006636:0.011015:0.010382:0.011118:0.005679
view. :@0.559983:0.285736:0.607687:0.285736:0.607687:0.271730:0.559983:0.271730:0.009476:0.003421:0.011118:0.014214:0.004738:0.004738
National Cancer Institute (Bethes-:@0.614888:0.285736:0.914539:0.285736:0.914539:0.271730:0.614888:0.271730:0.012657:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.011939:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.011939:0.003866:0.010434:0.006636:0.005798:0.003421:0.005798:0.010399:0.005798:0.011118:0.011939:0.006312:0.009818:0.011118:0.005798:0.010434:0.011118:0.006636:0.005679
da).1975-2005.:@0.559983:0.300188:0.680654:0.300188:0.680654:0.286183:0.559983:0.286183:0.011716:0.011682:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
3. :@0.523636:0.314640:0.542588:0.314640:0.542588:0.300635:0.523636:0.300635:0.009476:0.004738:0.004738
  DeVita VT, Hellman S, Rosenberg SA. :@0.559983:0.314640:0.877077:0.314640:0.877077:0.300635:0.559983:0.300635:0.004738:-0.004738:0.012726:0.011118:0.012094:0.003421:0.005798:0.011682:0.007406:0.012007:0.005540:0.004738:0.007406:0.011682:0.011118:0.003421:0.003421:0.016044:0.011682:0.010434:0.007406:0.008518:0.004738:0.007406:0.010382:0.011203:0.006636:0.011118:0.010434:0.011665:0.011118:0.005162:0.011511:0.007406:0.008518:0.012657:0.004738:0.004738
Prin-:@0.879745:0.314640:0.914553:0.314640:0.914553:0.300635:0.879745:0.300635:0.010126:0.005148:0.003421:0.010434:0.005679
ciples and  Practice  of  Oncology. :@0.559983:0.329092:0.850507:0.329092:0.850507:0.315087:0.559983:0.315087:0.011067:0.003421:0.011665:0.003421:0.011118:0.006636:0.007765:0.011682:0.010434:0.011716:0.004738:0.003017:0.010126:0.005148:0.011682:0.011067:0.005790:0.003421:0.011067:0.011118:0.004738:0.003017:0.011203:0.005371:0.004738:0.003012:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.004738
9th  ed. :@0.853511:0.329092:0.919282:0.329092:0.919282:0.315087:0.853511:0.315087:0.009476:0.005798:0.010434:0.004738:0.003015:0.011118:0.011716:0.004738:0.004738
Philadelphia:  Lippincott Williams  & Wilkins; :@0.559983:0.343544:0.919270:0.343544:0.919270:0.329539:0.559983:0.329539:0.010126:0.010434:0.003421:0.003421:0.011682:0.011716:0.011118:0.003421:0.011665:0.010434:0.003421:0.011682:0.004738:0.004738:0.002817:0.007902:0.003421:0.011665:0.011665:0.003421:0.010434:0.011067:0.011203:0.005798:0.005798:0.007543:0.016519:0.003421:0.003421:0.003421:0.003421:0.011682:0.016044:0.006636:0.004738:0.002827:0.012948:0.007543:0.016519:0.003421:0.003421:0.008586:0.003421:0.010434:0.006636:0.004738:0.004738
2011;1222-1269.:@0.559983:0.357996:0.688847:0.357996:0.688847:0.343991:0.559983:0.343991:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
4. :@0.523636:0.372448:0.542588:0.372448:0.542588:0.358443:0.523636:0.358443:0.009476:0.004738:0.004738
  Marcus PM, Kramer BS. :@0.559983:0.372448:0.756864:0.372448:0.756864:0.358443:0.559983:0.358443:0.004738:-0.004738:0.015719:0.011682:0.005029:0.011067:0.010399:0.006636:0.006243:0.010126:0.015719:0.004738:0.006233:0.010109:0.005148:0.011682:0.016044:0.011118:0.005148:0.006229:0.009818:0.008518:0.004738:0.004738
ASCO Educational :@0.758369:0.372448:0.919287:0.372448:0.919287:0.358443:0.758369:0.358443:0.012657:0.008518:0.013906:0.014864:0.006243:0.009168:0.011716:0.010399:0.011067:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.004738
Book:@0.559983:0.386901:0.600794:0.386901:0.600794:0.372895:0.559983:0.372895:0.009818:0.011203:0.011203:0.008586
. 2012;96-100.:@0.600794:0.386901:0.710706:0.386901:0.710706:0.372895:0.600794:0.372895:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
5. :@0.523636:0.401353:0.542588:0.401353:0.542588:0.387347:0.523636:0.387347:0.009476:0.004738:0.004738
  Epstein  JI,:@0.559983:0.401353:0.645236:0.401353:0.645236:0.387347:0.559983:0.387347:0.004738:-0.004738:0.009168:0.011665:0.006636:0.005798:0.011118:0.003421:0.010434:0.004738:0.005427:0.008244:0.003866:0.004738
 et al.:@0.645236:0.401353:0.702313:0.401353:0.702313:0.387347:0.645236:0.387347:0.010160:0.011118:0.005798:0.010160:0.011682:0.003421:0.004738
 Contemporary Gleason :@0.702313:0.401353:0.919287:0.401353:0.919287:0.387347:0.702313:0.387347:0.010160:0.013906:0.011203:0.010434:0.005798:0.011118:0.016044:0.011665:0.011191:0.005148:0.011682:0.005148:0.009168:0.010160:0.014915:0.003421:0.011118:0.011682:0.006636:0.011203:0.010434:0.004738
Grade  of  prostate  cancer. :@0.559983:0.415805:0.807808:0.415805:0.807808:0.401800:0.559983:0.401800:0.014915:0.005148:0.011682:0.011716:0.011118:0.004738:0.008249:0.011203:0.005371:0.004738:0.008248:0.011665:0.005080:0.011203:0.006636:0.005798:0.011682:0.005798:0.011118:0.004738:0.008246:0.011067:0.011682:0.010434:0.011067:0.011118:0.003890:0.004738:0.004738
Am  J  Surg :@0.816052:0.415805:0.919285:0.415805:0.919285:0.401800:0.816052:0.401800:0.012657:0.016044:0.004738:0.008246:0.008244:0.004738:0.008251:0.008518:0.010399:0.005148:0.011511:0.004738
Pathol.:@0.559983:0.430257:0.617385:0.430257:0.617385:0.416252:0.559983:0.416252:0.010126:0.011682:0.005798:0.010434:0.011203:0.003421:0.004738
 2017 Apr;41(4):e1-e7.:@0.617368:0.430257:0.796348:0.430257:0.796348:0.416252:0.617368:0.416252:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.012657:0.011665:0.005148:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.011118:0.009476:0.005679:0.011118:0.009476:0.004738
6. :@0.523636:0.444709:0.542588:0.444709:0.542588:0.430704:0.523636:0.430704:0.009476:0.004738:0.004738
 De Bono JS,:@0.559983:0.444709:0.670015:0.444709:0.670015:0.430704:0.559983:0.430704:0.000000:0.012726:0.011118:0.011015:0.009818:0.011203:0.010434:0.011203:0.011015:0.008244:0.008518:0.004738
 et al.:@0.670015:0.444709:0.728803:0.444709:0.728803:0.430704:0.670015:0.430704:0.011015:0.011118:0.005798:0.011015:0.011682:0.003421:0.004738
 Abiraterone and in-:@0.728803:0.444709:0.914532:0.444709:0.914532:0.430704:0.728803:0.430704:0.011015:0.012657:0.011665:0.003421:0.005148:0.011682:0.005798:0.011118:0.005073:0.011203:0.010434:0.011118:0.011015:0.011682:0.010434:0.011716:0.011015:0.003421:0.010434:0.005679
creased survival in metastatic prostate :@0.559983:0.459161:0.919285:0.459161:0.919285:0.445156:0.559983:0.445156:0.011067:0.005078:0.011118:0.011682:0.006636:0.011118:0.011716:0.013649:0.006636:0.010399:0.005148:0.009476:0.003421:0.009476:0.011693:0.003421:0.013649:0.003421:0.010434:0.013649:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.013649:0.011665:0.005080:0.011203:0.006636:0.005798:0.011682:0.005798:0.011118:0.004738
cancer. :@0.559983:0.473613:0.628715:0.473613:0.628715:0.459608:0.559983:0.459608:0.011067:0.011682:0.010434:0.011067:0.011118:0.003890:0.004738:0.004738
N Engl J Med:@0.628715:0.473613:0.736917:0.473613:0.736917:0.459608:0.628715:0.459608:0.012657:0.004738:0.009168:0.010434:0.011511:0.003421:0.004738:0.008244:0.004738:0.015719:0.011118:0.011716
. 2011;164(21):1995.:@0.736893:0.473613:0.896391:0.473613:0.896391:0.459608:0.736893:0.459608:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
7. :@0.523636:0.488066:0.542588:0.488066:0.542588:0.474060:0.523636:0.474060:0.009476:0.004738:0.004738
  Miller K,:@0.559983:0.488066:0.623594:0.488066:0.623594:0.474060:0.559983:0.474060:0.004738:-0.004738:0.015719:0.003421:0.003421:0.003421:0.011118:0.005148:0.006517:0.010109:0.004738
 et al.:@0.623594:0.488066:0.673376:0.488066:0.673376:0.474060:0.623594:0.474060:0.006517:0.011118:0.005798:0.006508:0.011682:0.003421:0.004738
 Phase III COU-AA-302, study :@0.673376:0.488066:0.919302:0.488066:0.919302:0.474060:0.673376:0.474060:0.006517:0.010126:0.010434:0.011682:0.006636:0.011118:0.006517:0.003866:0.003866:0.003866:0.006517:0.013906:0.014864:0.011203:0.005679:0.012657:0.012657:0.005679:0.009476:0.009476:0.009476:0.004738:0.006517:0.006636:0.005798:0.010399:0.011716:0.009168:0.004738
of abiraterone acetate plus prednisone in :@0.559983:0.502518:0.919291:0.502518:0.919291:0.488512:0.559983:0.488512:0.011203:0.005371:0.006517:0.011682:0.011665:0.003421:0.005148:0.011682:0.005798:0.011118:0.005077:0.011203:0.010434:0.011118:0.006517:0.011682:0.011067:0.011118:0.005798:0.011682:0.005798:0.011118:0.006517:0.011665:0.003421:0.010399:0.006636:0.006517:0.011665:0.005080:0.011118:0.011716:0.010434:0.003421:0.006636:0.011203:0.010434:0.011118:0.006517:0.003421:0.010434:0.004738
men with chemotherapy-naïve patients :@0.559983:0.516970:0.919294:0.516970:0.919294:0.502965:0.559983:0.502965:0.016044:0.011118:0.010434:0.013290:0.014214:0.003421:0.005798:0.010434:0.013290:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.005679:0.010434:0.011682:0.003421:0.009476:0.011118:0.013290:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004738
with metastatic castration  resistant  pros-:@0.559983:0.531422:0.914549:0.531422:0.914549:0.517417:0.559983:0.517417:0.014214:0.003421:0.005798:0.010434:0.010485:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.010485:0.011067:0.011682:0.006636:0.005798:0.005148:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.005735:0.005078:0.011118:0.006636:0.003421:0.006636:0.005798:0.011682:0.010434:0.005798:0.004738:0.005737:0.011665:0.005080:0.011203:0.006636:0.005679
tate cancer. :@0.559983:0.545874:0.669389:0.545874:0.669389:0.531869:0.559983:0.531869:0.005798:0.011682:0.005798:0.011118:0.006277:0.011067:0.011682:0.010434:0.011067:0.011118:0.003890:0.004738:0.004738
Eur Urol:@0.670928:0.545874:0.732897:0.545874:0.732897:0.531869:0.670928:0.531869:0.009168:0.010399:0.005148:0.006277:0.011203:0.005148:0.011203:0.003421
. 2017 September; pii: :@0.732897:0.545874:0.919299:0.545874:0.919299:0.531869:0.732897:0.531869:0.004738:0.006277:0.009476:0.009476:0.009476:0.009476:0.006293:0.008518:0.011118:0.011665:0.005798:0.011118:0.016044:0.011665:0.011118:0.005148:0.004738:0.006277:0.011665:0.003421:0.003421:0.004738:0.004738
S0302-2838(17)30728-5.:@0.559983:0.560326:0.748832:0.560326:0.748832:0.546321:0.559983:0.546321:0.008518:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.009476:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.004738
8. :@0.523636:0.574778:0.542588:0.574778:0.542588:0.560773:0.523636:0.560773:0.009476:0.004738:0.004738
  Scher  HI,:@0.559983:0.574778:0.639042:0.574778:0.639042:0.560773:0.559983:0.560773:0.004738:-0.004738:0.008518:0.011067:0.010434:0.011118:0.005148:0.004738:0.007752:0.011682:0.003866:0.004738
 et  al.:@0.639042:0.574778:0.700798:0.574778:0.700798:0.560773:0.639042:0.560773:0.012503:0.011118:0.005798:0.004738:0.007757:0.011682:0.003421:0.004738
 Increased survival with :@0.700798:0.574778:0.919284:0.574778:0.919284:0.560773:0.700798:0.560773:0.012503:0.003866:0.010434:0.011067:0.005075:0.011118:0.011682:0.006636:0.011118:0.011716:0.012503:0.006636:0.010399:0.005148:0.009476:0.003421:0.009476:0.011682:0.003421:0.012503:0.014214:0.003421:0.005798:0.010434:0.004738
enzalutamide in prostate  cancer  after :@0.559983:0.589230:0.919294:0.589230:0.919294:0.575225:0.559983:0.575225:0.011118:0.010434:0.007269:0.011682:0.003421:0.010399:0.005798:0.011682:0.016044:0.003421:0.011716:0.011118:0.014504:0.003421:0.010434:0.014504:0.011665:0.005080:0.011203:0.006636:0.005798:0.011682:0.005798:0.011118:0.004738:0.009758:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.009758:0.011682:0.005371:0.005798:0.011118:0.005148:0.004738
chemotherapy. :@0.559983:0.603683:0.694337:0.603683:0.694337:0.589677:0.559983:0.589677:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004738
N Engl J Med:@0.694337:0.603683:0.802605:0.603683:0.802605:0.589677:0.694337:0.589677:0.012657:0.004757:0.009168:0.010434:0.011511:0.003421:0.004762:0.008244:0.004760:0.015719:0.011118:0.011716
. 2012 Sep 27; :@0.802605:0.603683:0.919270:0.603683:0.919270:0.589677:0.802605:0.589677:0.004738:0.004758:0.009476:0.009476:0.009486:0.009476:0.004764:0.008518:0.011118:0.011665:0.004764:0.009476:0.009476:0.004738:0.004738
367(13):1187-97.:@0.559983:0.618135:0.691994:0.618135:0.691994:0.604129:0.559983:0.604129:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
9. :@0.523636:0.632587:0.542588:0.632587:0.542588:0.618582:0.523636:0.618582:0.009476:0.004738:0.004738
  Beer TM,:@0.559983:0.632587:0.631226:0.632587:0.631226:0.618582:0.559983:0.618582:0.004738:-0.004738:0.009818:0.011118:0.011118:0.005148:0.006298:0.007286:0.015719:0.004738
 et al.:@0.631226:0.632587:0.680584:0.632587:0.680584:0.618582:0.631226:0.618582:0.006303:0.011118:0.005798:0.006298:0.011682:0.003421:0.004738
 Enzalutamide in metastatic :@0.680584:0.632587:0.919291:0.632587:0.919291:0.618582:0.680584:0.618582:0.006301:0.009168:0.010434:0.007269:0.011682:0.003421:0.010399:0.005798:0.011682:0.016044:0.003421:0.011716:0.011118:0.006312:0.003421:0.010434:0.006303:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.004738
prostate cancer before chemotherapy.  :@0.559983:0.647039:0.919277:0.647039:0.919277:0.633034:0.559983:0.633034:0.011665:0.005080:0.011203:0.006636:0.005798:0.011682:0.005798:0.011118:0.013307:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.013307:0.011665:0.011118:0.005371:0.011203:0.005075:0.011118:0.013307:0.011067:0.010434:0.011118:0.016044:0.011195:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.000000:0.004738
N Engl J Med.:@0.559983:0.661491:0.672923:0.661491:0.672923:0.647486:0.559983:0.647486:0.012657:0.004738:0.009168:0.010434:0.011511:0.003421:0.004738:0.008244:0.004738:0.015719:0.011118:0.011716:0.004738
 2014;371:424-433.:@0.672906:0.661491:0.820722:0.661491:0.820722:0.647486:0.672906:0.647486:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
10.   de Bono J,:@0.523636:0.675943:0.646394:0.675943:0.646394:0.661938:0.523636:0.661938:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.011716:0.011118:0.003968:0.009818:0.011203:0.010434:0.011203:0.003968:0.008244:0.004738
 et al.:@0.646394:0.675943:0.691088:0.675943:0.691088:0.661938:0.646394:0.661938:0.003968:0.011118:0.005798:0.003968:0.011682:0.003421:0.004738
 Prednisone plus cabazitax-:@0.691088:0.675943:0.914551:0.675943:0.914551:0.661938:0.691088:0.661938:0.003968:0.010126:0.005075:0.011118:0.011716:0.010434:0.003421:0.006636:0.011203:0.010434:0.011118:0.003968:0.011665:0.003421:0.010399:0.006636:0.003968:0.011067:0.011682:0.011665:0.011682:0.007269:0.003421:0.005798:0.011682:0.008210:0.005679
el or mitoxantrone for metastatic castration :@0.559983:0.690395:0.919297:0.690395:0.919297:0.676390:0.559983:0.676390:0.011118:0.003421:0.003934:0.011203:0.005148:0.003922:0.016044:0.003421:0.005798:0.011203:0.008210:0.011682:0.010434:0.005798:0.005071:0.011203:0.010434:0.011118:0.003920:0.005371:0.011203:0.005148:0.003920:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.003934:0.011067:0.011682:0.006636:0.005798:0.005148:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738
resistant prostate cancer progressing after :@0.559983:0.704847:0.919299:0.704847:0.919299:0.690842:0.559983:0.690842:0.005078:0.011118:0.006636:0.003421:0.006636:0.005798:0.011682:0.010434:0.005798:0.006277:0.011665:0.005080:0.011203:0.006636:0.005798:0.011682:0.005798:0.011118:0.006267:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.006260:0.011665:0.005080:0.011203:0.011511:0.005071:0.011118:0.006636:0.006636:0.003421:0.010434:0.011511:0.006269:0.011682:0.005371:0.005798:0.011118:0.005148:0.004738
docetaxel treatment: a randomised open-:@0.559983:0.719300:0.914551:0.719300:0.914551:0.705294:0.559983:0.705294:0.011716:0.011203:0.011067:0.011118:0.005798:0.011682:0.008210:0.011118:0.003421:0.005183:0.005798:0.005075:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738:0.005183:0.011682:0.005183:0.005148:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.006636:0.011118:0.011716:0.005183:0.011203:0.011665:0.011118:0.010434:0.005679
label trial. :@0.559983:0.733752:0.644974:0.733752:0.644974:0.719746:0.559983:0.719746:0.003421:0.011682:0.011665:0.011118:0.003421:0.004738:0.005798:0.005148:0.003421:0.011682:0.003421:0.004738:0.004738
Lancet.:@0.644974:0.733752:0.707713:0.733752:0.707713:0.719746:0.644974:0.719746:0.007902:0.011682:0.010434:0.011067:0.011118:0.005798:0.004738
 2010;376(9747):1147.:@0.707713:0.733752:0.881425:0.733752:0.881425:0.719746:0.707713:0.719746:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
11.   Parker  C,:@0.523636:0.748204:0.638180:0.748204:0.638180:0.734199:0.523636:0.734199:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010126:0.011682:0.005148:0.008586:0.011118:0.005148:0.004738:0.003007:0.013906:0.004738
  et  al.:@0.638180:0.748204:0.690446:0.748204:0.690446:0.734199:0.638180:0.734199:0.004738:0.003019:0.011118:0.005798:0.004738:0.003014:0.011682:0.003421:0.004738
  Alpha  emitter  radium-223 :@0.690446:0.748204:0.919268:0.748204:0.919268:0.734199:0.690446:0.734199:0.004738:0.003019:0.012657:0.003421:0.011665:0.010434:0.011682:0.004738:0.003019:0.011118:0.016044:0.003421:0.005798:0.005798:0.011118:0.005148:0.004738:0.003010:0.005148:0.011682:0.011716:0.003421:0.010399:0.016044:0.005679:0.009476:0.009476:0.009476:0.004738
and survival in metastatic prostate cancer. :@0.559983:0.762656:0.919285:0.762656:0.919285:0.748651:0.559983:0.748651:0.011682:0.010434:0.011716:0.005037:0.006636:0.010399:0.005148:0.009476:0.003421:0.009476:0.011682:0.003421:0.005046:0.003421:0.010434:0.005037:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.005046:0.011665:0.005080:0.011203:0.006636:0.005798:0.011682:0.005798:0.011118:0.005032:0.011067:0.011682:0.010434:0.011067:0.011118:0.003888:0.004738:0.004738
N Engl J Med:@0.559983:0.777108:0.668185:0.777108:0.668185:0.763103:0.559983:0.763103:0.012657:0.004738:0.009168:0.010434:0.011511:0.003421:0.004738:0.008244:0.004738:0.015719:0.011118:0.011716
. 2013 Jul;369(3):213-23.:@0.668168:0.777108:0.860147:0.777108:0.860147:0.763103:0.668168:0.763103:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.008244:0.010399:0.003421:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
.:@0.523636:0.791560:0.528374:0.791560:0.528374:0.777555:0.523636:0.777555:0.004738
Acknowledgement:  Prof JP Jordaan, former :@0.523636:0.806012:0.919302:0.806012:0.919302:0.792007:0.523636:0.792007:0.012657:0.011067:0.008586:0.010434:0.011203:0.014214:0.003421:0.011118:0.011716:0.011511:0.011118:0.016044:0.011118:0.010434:0.005798:0.004738:0.004738:0.006837:0.010126:0.005075:0.011203:0.005371:0.011597:0.008244:0.010126:0.011597:0.008244:0.011203:0.005041:0.011716:0.011682:0.011682:0.010434:0.004738:0.011597:0.005371:0.011203:0.005617:0.016044:0.011118:0.005148:0.004738
Head Department of Oncology, School of Clini-:@0.523636:0.820464:0.914544:0.820464:0.914544:0.806459:0.523636:0.806459:0.011682:0.011118:0.011682:0.011716:0.004396:0.012726:0.011118:0.011665:0.011682:0.005148:0.005798:0.016044:0.011118:0.010434:0.005798:0.004377:0.011203:0.005371:0.004382:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.004379:0.008518:0.011067:0.010434:0.011203:0.011203:0.003421:0.004379:0.011203:0.005371:0.004382:0.013906:0.003421:0.003421:0.010434:0.003421:0.005679
cal Medicine, University of KwaZulu Natal.:@0.523636:0.834917:0.867057:0.834917:0.867057:0.820911:0.523636:0.820911:0.011067:0.011682:0.003421:0.004738:0.015719:0.011118:0.011716:0.003421:0.011067:0.003421:0.010434:0.011118:0.004738:0.004738:0.011203:0.010434:0.003421:0.009476:0.011118:0.005148:0.006636:0.003421:0.005798:0.009168:0.004738:0.011203:0.005371:0.004738:0.010109:0.014214:0.011682:0.008210:0.010399:0.003421:0.010399:0.004738:0.012657:0.011682:0.005798:0.011682:0.003421:0.004738